Nucl Med Mol Imaging.  2017 Mar;51(1):22-31. 10.1007/s13139-016-0411-3.

FDG Whole-Body PET/MRI in Oncology: a Systematic Review

• Kwon HW
• Becker AK
• Goo JM
• Cheon GJ

• KMID: 2373453
• DOI: http://doi.org/10.1007/s13139-016-0411-3

Abstract

The recent advance in hybrid imaging techniques enables offering simultaneous positron emission tomography (PET)/magnetic resonance imaging (MRI) in various clinical fields. ¹â¸F-fluorodeoxyglucose (FDG) PET has been widely used for diagnosis and evaluation of oncologic patients. The growing evidence from research and clinical experiences demonstrated that PET/MRI with FDG can provide comparable or superior diagnostic performance more than conventional radiological imaging such as computed tomography (CT), MRI or PET/CT in various cancers. Combined analysis using structural information and functional/molecular information of tumors can draw additional diagnostic information based on PET/MRI. Further studies including determination of the diagnostic efficacy, optimizing the examination protocol, and analysis of the hybrid imaging results is necessary for extending the FDG PET/MRI application in clinical oncology.

Keyword

FDG; Oncology; PET/MRI; Positron emission tomography/magnetic resonance imaging

MeSH Terms

Diagnosis
Humans
Magnetic Resonance Imaging
Medical Oncology
Positron-Emission Tomography
Positron-Emission Tomography and Computed Tomography